JP2008531599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531599A5 JP2008531599A5 JP2007557244A JP2007557244A JP2008531599A5 JP 2008531599 A5 JP2008531599 A5 JP 2008531599A5 JP 2007557244 A JP2007557244 A JP 2007557244A JP 2007557244 A JP2007557244 A JP 2007557244A JP 2008531599 A5 JP2008531599 A5 JP 2008531599A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- independently
- halo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910005965 SO 2 Inorganic materials 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 5
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical class [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- CSXHUONYHRDYGM-UHFFFAOYSA-N 2-(hydroxyamino)-2-oxoacetic acid Chemical compound ONC(=O)C(O)=O CSXHUONYHRDYGM-UHFFFAOYSA-N 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- -1 hydroxy, carboxy Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims 1
- MJBZOGYMRBOHPX-UHFFFAOYSA-N 2-[amino(cyano)amino]-2-oxoacetic acid Chemical compound NN(C(=O)C(=O)O)C#N MJBZOGYMRBOHPX-UHFFFAOYSA-N 0.000 claims 1
- ZFVRYNYOPQZKDG-UHFFFAOYSA-N 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1NC1CCC(O)CC1 ZFVRYNYOPQZKDG-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65623005P | 2005-02-25 | 2005-02-25 | |
| US70571505P | 2005-08-04 | 2005-08-04 | |
| US72796505P | 2005-10-18 | 2005-10-18 | |
| PCT/US2006/006988 WO2006091963A1 (en) | 2005-02-25 | 2006-02-27 | Tetrahydroindolone and tetrahydroindazolone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008531599A JP2008531599A (ja) | 2008-08-14 |
| JP2008531599A5 true JP2008531599A5 (enExample) | 2009-05-14 |
| JP4377942B2 JP4377942B2 (ja) | 2009-12-02 |
Family
ID=36581601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557244A Expired - Fee Related JP4377942B2 (ja) | 2005-02-25 | 2006-02-27 | テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US7358370B2 (enExample) |
| EP (2) | EP1856057B1 (enExample) |
| JP (1) | JP4377942B2 (enExample) |
| KR (3) | KR101617774B1 (enExample) |
| CN (1) | CN101180275B (enExample) |
| AR (1) | AR054186A1 (enExample) |
| AU (2) | AU2006216441B2 (enExample) |
| BR (1) | BRPI0607739A2 (enExample) |
| CA (1) | CA2598993C (enExample) |
| DK (1) | DK1856057T3 (enExample) |
| EA (1) | EA013521B1 (enExample) |
| ES (1) | ES2527770T3 (enExample) |
| GE (1) | GEP20104994B (enExample) |
| IL (1) | IL185280A (enExample) |
| MA (1) | MA29713B1 (enExample) |
| MX (1) | MX2007010227A (enExample) |
| NO (1) | NO20074274L (enExample) |
| NZ (2) | NZ560685A (enExample) |
| PL (1) | PL1856057T3 (enExample) |
| PT (1) | PT1856057E (enExample) |
| SI (1) | SI1856057T1 (enExample) |
| TW (1) | TWI382015B (enExample) |
| UA (1) | UA92907C2 (enExample) |
| WO (1) | WO2006091963A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| KR20070060156A (ko) * | 2004-10-04 | 2007-06-12 | 미리어드 제네틱스, 인크. | 알츠하이머병 치료용 화합물 |
| JP4377942B2 (ja) | 2005-02-25 | 2009-12-02 | セレネックス， インコーポレイテッド | テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体 |
| DE602006021306D1 (enExample) * | 2005-06-27 | 2011-05-26 | Bristol Myers Squibb Co | |
| CA2642931A1 (en) * | 2006-02-27 | 2007-09-07 | Serenex, Inc. | Cyclohexylamino, benzene, pyridine, and pyridazine derivatives |
| WO2007120669A1 (en) * | 2006-04-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| NZ572600A (en) | 2006-05-12 | 2011-08-26 | Myrexis Inc | 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders |
| MX2008014672A (es) * | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| US20080070918A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives |
| WO2008024963A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| CA2661436A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
| WO2008024978A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| WO2008024980A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| WO2008024981A1 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Piperazine-substituted benzothiophenes for treatment of mental disorders |
| US20080076813A1 (en) * | 2006-08-24 | 2008-03-27 | Huang Kenneth H | Benzene, Pyridine, and Pyridazine Derivatives |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| US20100280032A1 (en) * | 2006-10-26 | 2010-11-04 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CN101273991B (zh) * | 2007-03-28 | 2010-05-26 | 广东同德药业有限公司 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
| US20080269193A1 (en) * | 2007-04-16 | 2008-10-30 | Kenneth He Huang | Tetrahydroindole and Tetrahydroindazole Derivatives |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| WO2009051244A1 (ja) * | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| BRPI1009375A2 (pt) * | 2009-03-19 | 2016-03-15 | Sanofi Aventis | derivados inibidores de hsp90, composições que os contém e utilização |
| FR2955323B1 (fr) * | 2010-01-19 | 2015-01-16 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| FR2943341B1 (fr) * | 2009-03-19 | 2011-03-11 | Sanofi Aventis | Nouveaux derives d'indazole inhibiteurs d'hsp90,compositions les contenant et utilisation |
| EP3578664B1 (en) * | 2009-03-30 | 2024-10-30 | Nordic Bioscience A/S | Collagen iv neo-epitope fibrosis assay |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| CN101872359B (zh) * | 2010-06-11 | 2013-08-14 | 北京邮电大学 | 实现演变点发现的社会网络演化分析方法及系统 |
| CN102311389A (zh) * | 2010-06-29 | 2012-01-11 | 王小龙 | 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用 |
| CN101967125B (zh) | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| CN101955461B (zh) * | 2010-10-08 | 2012-11-21 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
| MX2013010524A (es) | 2011-03-15 | 2013-12-06 | Univ British Columbia | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. |
| CN102675288B (zh) * | 2011-03-18 | 2014-01-01 | 北京师范大学 | 2-((2-(双(2-吡啶甲基)氨基)乙基)氨基)-4-(3，6，6-三甲基-4-氧-4，5，6，7-四氢吲唑基)苯甲酰胺及制备、应用 |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| EP2879675B1 (en) | 2012-08-06 | 2019-11-13 | Duke University | Compounds and methods for targeting hsp90 |
| CN103467356B (zh) * | 2013-08-12 | 2015-04-01 | 绍兴文理学院 | 一种四氢吲哚化合物及其制备方法与应用 |
| WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| US10246421B2 (en) * | 2014-09-11 | 2019-04-02 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
| US20160143884A1 (en) * | 2014-11-26 | 2016-05-26 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
| CN104592203A (zh) * | 2015-01-30 | 2015-05-06 | 广州暨南生物医药研究开发基地有限公司 | 一种2-氨基-4-四氢吲唑取代的苯甲酰胺化合物及其在制备抗肿瘤药物中的应用 |
| CN104592230B (zh) * | 2015-01-30 | 2017-02-01 | 广州暨南生物医药研究开发基地有限公司 | 一种2‑（石榴皮烷‑3‑氨基）‑4‑四氢吲唑取代的苯甲酰胺化合物及其应用 |
| WO2016191412A1 (en) * | 2015-05-26 | 2016-12-01 | University Of South Florida | Antimicrobial compositions, methods of use, and methods of treatment of infections |
| WO2017059434A1 (en) | 2015-10-02 | 2017-04-06 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of cancer |
| CA3000803C (en) * | 2015-10-13 | 2020-03-24 | Nihon Nohyaku Co., Ltd. | Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide |
| US11261187B2 (en) | 2016-04-22 | 2022-03-01 | Duke University | Compounds and methods for targeting HSP90 |
| US20190134003A1 (en) * | 2016-05-18 | 2019-05-09 | Esanex, Inc. | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer |
| KR20190064602A (ko) | 2016-09-23 | 2019-06-10 | 에사넥스, 인코포레이티드 | 암의 치료를 위한 인다졸릴벤즈아미드 유도체를 사용한 조합 요법 |
| JP6594570B2 (ja) | 2017-03-20 | 2019-10-23 | フォーマ セラピューティクス，インコーポレイテッド | ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物 |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| AU2020350763A1 (en) | 2019-09-19 | 2022-04-07 | Novo Nordisk Health Care Ag | Pyruvate kinase R (PKR) activating compositions |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JOP20220160A1 (ar) | 2019-12-20 | 2023-01-30 | Nuevolution As | مركبات فعّالة نحو مستقبلات نووية |
| MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| CN119431335A (zh) * | 2020-06-11 | 2025-02-14 | 贝达药业股份有限公司 | 双环化合物及其应用 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN114213332B (zh) * | 2022-02-21 | 2022-05-17 | 深圳市人民医院 | 一种四氢吲唑类化合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4024862A1 (de) * | 1990-08-04 | 1992-02-13 | Hoechst Ag | 4,5,6,7-tetrahydro-3-aryl-indazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| GB9812038D0 (en) * | 1998-06-04 | 1998-07-29 | Merck Sharp & Dohme | Therapeutic compound |
| GB9900222D0 (en) * | 1999-01-06 | 1999-02-24 | Merck Sharp & Dohme | Therapeutic compounds |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| AU2001290641A1 (en) * | 2000-09-06 | 2002-03-22 | Neurogen Corporation | Substituted fused pyrroleimines and pyrazoleimines |
| BR0211810A (pt) * | 2001-08-09 | 2004-08-24 | Ono Pharmaceutical Co | Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo |
| DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AU2003217870A1 (en) * | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pini-modulating compounds and methods of use thereof |
| JP4666256B2 (ja) | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
| PE20040804A1 (es) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| JP4377942B2 (ja) * | 2005-02-25 | 2009-12-02 | セレネックス， インコーポレイテッド | テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体 |
| US7803822B2 (en) | 2005-04-06 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Triazole derivative and use thereof |
| US20080269193A1 (en) * | 2007-04-16 | 2008-10-30 | Kenneth He Huang | Tetrahydroindole and Tetrahydroindazole Derivatives |
-
2006
- 2006-02-27 JP JP2007557244A patent/JP4377942B2/ja not_active Expired - Fee Related
- 2006-02-27 AR ARP060100720A patent/AR054186A1/es not_active Application Discontinuation
- 2006-02-27 PT PT67363309T patent/PT1856057E/pt unknown
- 2006-02-27 KR KR1020137020400A patent/KR101617774B1/ko not_active Expired - Fee Related
- 2006-02-27 BR BRPI0607739-0A patent/BRPI0607739A2/pt not_active Application Discontinuation
- 2006-02-27 TW TW095106716A patent/TWI382015B/zh not_active IP Right Cessation
- 2006-02-27 KR KR1020157005119A patent/KR20150029766A/ko not_active Abandoned
- 2006-02-27 AU AU2006216441A patent/AU2006216441B2/en not_active Ceased
- 2006-02-27 EA EA200701808A patent/EA013521B1/ru not_active IP Right Cessation
- 2006-02-27 US US11/363,449 patent/US7358370B2/en active Active
- 2006-02-27 DK DK06736330.9T patent/DK1856057T3/en active
- 2006-02-27 SI SI200631875T patent/SI1856057T1/sl unknown
- 2006-02-27 NZ NZ560685A patent/NZ560685A/en not_active IP Right Cessation
- 2006-02-27 PL PL06736330T patent/PL1856057T3/pl unknown
- 2006-02-27 NZ NZ588960A patent/NZ588960A/en not_active IP Right Cessation
- 2006-02-27 ES ES06736330.9T patent/ES2527770T3/es active Active
- 2006-02-27 GE GEAP200610280A patent/GEP20104994B/en unknown
- 2006-02-27 EP EP06736330.9A patent/EP1856057B1/en active Active
- 2006-02-27 MX MX2007010227A patent/MX2007010227A/es active IP Right Grant
- 2006-02-27 KR KR1020077021820A patent/KR20070114763A/ko not_active Ceased
- 2006-02-27 CA CA2598993A patent/CA2598993C/en active Active
- 2006-02-27 WO PCT/US2006/006988 patent/WO2006091963A1/en not_active Ceased
- 2006-02-27 UA UAA200710606A patent/UA92907C2/uk unknown
- 2006-02-27 EP EP11173186.5A patent/EP2380879B1/en active Active
- 2006-02-27 CN CN200680010486.0A patent/CN101180275B/zh not_active Expired - Fee Related
-
2007
- 2007-08-14 IL IL185280A patent/IL185280A/en not_active IP Right Cessation
- 2007-08-22 NO NO20074274A patent/NO20074274L/no not_active Application Discontinuation
- 2007-09-11 MA MA30216A patent/MA29713B1/fr unknown
- 2007-12-19 US US11/959,784 patent/US7906529B2/en not_active Expired - Fee Related
-
2010
- 2010-10-19 US US12/907,571 patent/US7928135B2/en active Active
-
2011
- 2011-04-07 US US13/081,637 patent/US8309548B2/en not_active Expired - Fee Related
- 2011-04-15 AU AU2011201700A patent/AU2011201700B2/en not_active Ceased
-
2012
- 2012-11-05 US US13/669,016 patent/US20130137686A1/en not_active Abandoned
-
2014
- 2014-08-04 US US14/451,033 patent/US9656956B2/en not_active Expired - Fee Related
-
2017
- 2017-05-22 US US15/601,428 patent/US20170260174A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/408,959 patent/US20200071308A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531599A5 (enExample) | ||
| JP2013544276A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2017511794A5 (enExample) | ||
| JP2013530176A5 (enExample) | ||
| JP2010031025A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2017528467A5 (enExample) | ||
| JP2016506369A5 (enExample) | ||
| JP2015509534A5 (enExample) | ||
| JP2011517453A5 (enExample) | ||
| JP2014500265A5 (enExample) | ||
| JP2006522035A5 (enExample) | ||
| ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
| JP2017526677A5 (enExample) | ||
| JP2013536188A5 (enExample) | ||
| JP2016501185A5 (enExample) | ||
| EA200971080A1 (ru) | Кристаллическое соединение пиридазина | |
| JP2014518212A5 (ja) | 化合物及び組成物 | |
| JP2012507535A5 (enExample) | ||
| JP2005517643A5 (enExample) | ||
| JP2013542980A5 (enExample) | ||
| JP2009501745A5 (enExample) |